Online inquiry

IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5566MR)

This product GTTS-WQ5566MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD33 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001082618.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 945
UniProt ID P20138
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ5566MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10739MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA M-6495
GTTS-WQ6060MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO 888
GTTS-WQ8991MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMA-638
GTTS-WQ2296MR IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ALXN-1210
GTTS-WQ10795MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA M777-16-3
GTTS-WQ13909MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN2477
GTTS-WQ13564MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PRX-302
GTTS-WQ11033MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MCLA-128
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW